BMS Logo Bristol-Myers

News

Bristol Myers Squibb, BioNTech and cancer immunotherapy

NJBIZ · 1d

Bristol Myers Squibb, BioNTech partner on $11B cancer drug deal

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Reuters on MSN · 3d

Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy

By Ludwig Burger and Michael Erman (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy,

Barchart on MSN · 23h

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?

Myers Squibb Company (BMY) is a global biopharmaceutical company. With a market cap of $97.9 billion, the company engages in the discovery, development, licensing, manufacturing, marketing, distribution,

pharmaphorum5d

A history of Bristol-Myers Squibb

Bristol-Myers Squibb was founded in 1858 and has grown ... Around the same time, the prototype of the Squibb logo was designed. The logo represented product uniformity, purity, efficacy and ...

Yahoo Finance1y

Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal

(Reuters) — Bristol-Myers Squibb (BMY) on Sunday said it will acquire cancer drugmaker Mirati Therapeutics (MRTX) for up to $5.8 billion, diversifying its oncology business and adding drugs it ...

Forbes2y

Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?

We believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its industry peer, Eli Lilly stock (NYSE: LLY), given its better growth prospects. Eli Lilly is trading at 10 ...

The Motley Fool1y

Why Bristol Myers Squibb Stock Is Fading Today

Bristol Myers Squibb and Johnson & Johnson are co-developing a therapy that belongs to the same class as asundexian. The market took the news as a bad omen for BMS and J&J's rival therapy.

MedCity News4mon

Bristol Myers Squibb

2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma. Bristol Myers Squibb’s Opdualag paired with blockbuster immunotherapy Opdivo failed a clinical trial ...

Forbes2y

Does Bristol Myers Squibb Stock Have More Room For Growth?

Bristol Myers Squibb stock (NYSE: BMY) has seen a fall of 3% in a month, compared with -4% returns for the broader S&P500 index. The company reported upbeat Q4 results last month and has a solid ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results